Success Story: Advancing Cancer Immunotherapy Research Leads to NIW Approval for a Biochemistry and Molecular Biology Researcher
Client’s Testimonial:
"Thank you very much for your message and for all your assistance with my EB-2 NIW petition. I am extremely happy that my I-140 has been approved, and I truly appreciate the professionalism, guidance, and support your team provided throughout the entire process."
On July 31st, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Researcher in the Field of Biochemistry and Molecular Biology (Approval Notice).
General Field: Biochemistry and Molecular Biology
Position at the Time of Case Filing: Postdoctoral Researcher
Country of Origin: Egypt
State of Residence at the Time of Filing: Pennsylvania
Approval Notice Date: July 31st, 2026
Processing Time: 19 months, 8 days (Premium Processing Requested)
Case Summary:
Cancer research often advances by uncovering the molecular processes that allow tumors to develop, evade immune responses, and resist treatment. For this NIW case, our client proposed to investigate the mechanisms of tumor development in complex malignancies, with the goal of developing more effective cancer immunotherapies and improving the fundamental understanding of immune system genetics. North America Immigration Law Group (Chen Immigration Law Associates) presented the endeavor as one with implications for cancer treatment, diagnostics, and patient outcomes in the United States. A premium processing upgrade was submitted on June 3rd, 2026. The petition was approved on July 31st, 2026, following a total processing period of 19 months and 8 days.
Connecting Cancer Biology with Better Treatment Strategies
The client's proposed research focused on understanding the complex interplay between malignancies and the immune system. The client's plans included investigating mechanisms of immune evasion in severe cancers, developing more effective targeted immunotherapies, studying cellular genetic diversification and tumor development, and using patient-derived clinical data to identify factors associated with therapeutic efficacy or resistance. We emphasized the broader importance of this work given the substantial public health burden associated with these diseases and the continuing need for more effective treatments.
An expert in the field summarized the potential significance of the client's work:
“[Client]'s achievements underscore the crucial role of his research in advancing cancer treatment and improving patient outcomes in the United States.”
A Research Record Already Influencing the Field
The client's ability to continue this work was supported by an extensive record of scholarship and independent recognition. At the time of filing, the evidence included:
- A Ph.D. in biochemistry and molecular biology
- 53 peer-reviewed journal articles
- 14 book chapters
- 712 citations to the client's publications
- 38 completed peer reviews for scientific journals
- Support from the Lions Research Fund
Building on a Foundation of Cancer Research
The client's prior projects established clear continuity between past achievements and future plans. Their research had examined the role of key molecular factors in various aggressive cancers, potential approaches to overcoming drug resistance, protective compounds against tumor development, and the role of specific proteins in cancer progression. These studies generated findings that other researchers subsequently applied when investigating targeted cancer therapies, tumor biology, drug delivery, and related molecular pathways. This record helped us demonstrate that the proposed endeavor represented a natural continuation of an established research trajectory rather than an entirely prospective goal.
NIW Approval After a 19-Month Journey
The case ultimately connected three complementary elements: an established record of cancer research, measurable reliance on the client's work by other scientists, and a future endeavor directed toward important unresolved questions in cancer immunology and treatment. By presenting these elements together, we demonstrated why the client was well-positioned to continue investigating tumorigenesis and immune evasion while pursuing more effective therapeutic strategies. We are pleased to have supported the client through this process and wish them continued success in advancing research that may contribute to improved cancer treatment and patient outcomes.
- NIW,
- Chemistry (Organic Chemistry, Biochemistry, Biochemical Engineering, Electrochemical Engineering, Physical Chemistry, Macromolecular Engineering, Polymer Chemistry, Chemical Engineering),
- Biology (Pathology and Immunology, Human Genetics, Genomics, Molecular Biology, Animal, Plant, Microbiology, Genetics, Botany)